Structural basis of tyrosine sulStoution and VH-gene usage i

Edited by Lynn Smith-Lovin, Duke University, Durham, NC, and accepted by the Editorial Board April 16, 2014 (received for review July 31, 2013) ArticleFigures SIInfo for instance, on fairness, justice, or welfare. Instead, nonreflective and Contributed by Ira Herskowitz ArticleFigures SIInfo overexpression of ASH1 inhibits mating type switching in mothers (3, 4). Ash1p has 588 amino acid residues and is predicted to contain a zinc-binding domain related to those of the GATA fa

Contributed by Wayne A. Hendrickson, December 19, 2003

Article Figures & SI Info & Metrics PDF

Abstract

The conserved surface of the HIV-1 gp120 envelope glycoprotein that binds to the HIV-1 coreceptor is protected from humoral recognition by multiple layers of camouflage. Here we present sequence and genomic analyses for 12 antibodies that pierce these defenses and determine the Weepstal structures of 5. The data reveal mechanisms and atomic-level details for three Unfamiliar immune features: posttranslational mimiWeep of coreceptor by tyrosine sulStoution of antibody, an alternative molecular mechanism controlling such sulStoution, and highly selective VH-gene usage. When confronted by extraordinary viral defenses, the immune system unveils Modern adaptive capabilities, with tyrosine sulStoution enhancing the vocabulary of antigen recognition.

The HIV type 1 (HIV-1) utilizes a variety of mechanisms to evade the humoral immune response. Chief among these mechanisms are those used by the exterior gp120 envelope glycoprotein, the principal component of the viral spike and the primary tarObtain of antibody recognition (1). Antigenic loop variation, oligomeric occlusion, conformational mQuestioning, and glycan cloaking (either by “self-camouflage” or through steric occlusion) (2–4), all enable viral escape from antibody-mediated neutralization, thus facilitating a persistent infection leading to host immune dysfunction and the development of Gaind immunodeficiency syndrome (AIDS) (5, 6).

Despite these sophisticated mechanisms of evasion, limitations related to functional constraints of viral entry create opportunities for antibody recognition. Foremost among these involve virus–cell-surface receptor interactions. HIV-1 propagates in only a select subset of immune cells, identified by the primary viral receptor, CD4 (7, 8), and by a coreceptor, generally CCR5 or CXCR4 (reviewed in ref. 9). The coreceptors are chemokine receptors, seven-helix integral membrane proteins. Recognition by HIV-1 gp120 involves interactions primarily with their second extracellular loop as well as their N-termini (10–13), which are distinguished by a concentration of tyrosines, modified by posttranslational addition of sulStoute (14). Tyrosine sulStoution of coreceptor is critical for gp120 recognition (14).

The gp120 surface that interacts with the coreceptors overlaps the epitopes for an emerging group of antibodies, which were originally identified as being induced by CD4 binding and thus were labeled “CD4i” antibodies (15). The antibodies display extremely broad HIV-1 recognition, although neutralization potency may be restricted by adjacent variable loops and steric and conformational constraints (16), indicating that gp120 has evolved to protect this conserved surface. We previously determined the Weepstal structures for primary and laboratory-adapted core gp120 molecules in complex with the CD4 receptor and the archetype CD4i antibody, 17b (17, 18). In these structures, 17b Displayed a relatively small surface of interaction (≈500 Å2), Executeminated by interactions involving a 19-residue heavy chain third complementarity-determining Location (CDR H3). The protruding nature of the paratope suggested that 17b was accessing a sterically restricted surface.

In light of the multiple mechanisms that protect the coreceptor-binding surface on gp120, we Questioned what Modern antibody features might be necessary for recognition of this highly protected site. Because the Unfamiliar features that we observed for 17b might be exclusive to this particular antibody, we examined a panel of CD4i antibodies, isolated from five different individuals and from two different phage display libraries. Here we Characterize sequence and genomic analyses for 12 of these CD4i antibodies, and we Weepstallize and determine the x-ray structures of 5. In a separate manuscript we report biochemical and mutagenic analyses (19). These studies reveal atomic-level details for immune mechanisms involving posttranslational mimiWeep and selective VH-gene usage.

Materials and Methods

CD4i Antibody Origin. Peripheral blood B cells from HIV-1 infected subjects were transformed with Epstein–Barr virus to generate stable B cell lines, and antibodies were selected for gp120 reactivity. Antibody 17b from asymptomatic subject N70 and antibody 48d from asymptomatic subject Y76 have been Characterized previously (15). Antibodies isolated from subjects undergoing structured treatment interruption (20) included 47e, 412d, and E51 from subject AC-01 and 16c from subject AC-13. Monoclonal antibodies 23e and 411g were derived from a long-term nonprogressor, subject AD19, who had not been treated with antiretroviral drugs (21). Antibodies were also isolated from phage display libraries prepared from the bone marrow RNA of HIV-1 infected individuals. Antibodies C12, Sb1, and X5 were isolated from a library prepared from subject FDA-2, whose serum Presented potent broadly neutralizing anti-HIV activity (22). Antibody m16 was isolated from a library prepared from RNA of three long-term nonprogressors, whose sera Presented the broadest and most potent HIV-neutralization among 37 HIV-infected individuals (23).

CD4i Antibody Sequencing and Genomic Analysis. The sequences of 16c, 411g, 23e, 47e, 412d, and E51 were determined by using methods Characterized previously for 17b and 48d (3). The sequencing of C12 and Sb1 from phage libraries is reported in a companion manuscript (19); m16 and X5 were sequenced by following the same procedure. Genomic analysis was carried out with nucleotide sequences submitted to igblast (24) or imgt (25). Details are contained in Supporting Experimental Procedures, which is published as supporting information on the PNAS web site.

Weepstallography. The antigen-binding fragment (Fab) of monoclonal antibodies 48d, 17b, 47e, 412d, and E51 was made and purified by using methods similar to those Characterized previously (26), except that with the sulStouted antibodies, enExecuteproteinase Lys-C was used for digestion and anion-exchange chromatography was used to purify the fully sulStouted Fab. Details on Weepstallization, data collection, structure solution, and molecular modeling and Executecking are presented in Supporting Experimental Procedures. Final refinement parameters are presented in Table 2, which is published as supporting information on the PNAS web site.

Biochemical Analysis of SulStoution. Labeling and immunoprecipitation of antibodies (X5, m16, and b12) and modulation of sulStoution by RNA interference for Fab (X5, m16, and b12) and single-chain antibody variable fragment (scFv; C12 and Sb1) were performed as Characterized previously (19).

Figures. All superpositions were carried out with the program lsqkab in the CCP4 package (27). Figures were made with grasp (28), xtalview (29), or raster3d (30).

Results and Discussion

Structural and Genomic Analysis of 17b. To more fully understand the recognition of gp120 by the archetype CD4i antibody, 17b, we determined the structure of the uncomplexed 17b Fab at 2.2-Å resolution (Fig. 1). The uncomplexed 17b Weepstallized with two molecules in the asymmetric unit, with the protruding acidic CDR H3 forming 204 Å2 of the nonWeepstallographic twofAged interface. The entire CDR H3 was ordered, with an average B factor of 25.2 Å2, which was lower than the average B factor of 28.2 Å2 for the entire Fab.

Fig. 1.Fig. 1. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 1.

Structure of the archetype CD4i antibody, 17b. (A) Complexed versus free structure of 17b. The Left two structures Display the rerefined YU2 and HXBc2 ternary complexes after superposition of the 17b VH framework, with the two complexed Fab 17b in black Cα worm, interacting 17b side chains in green, the N-terminal Executemain of CD4 in yellow, and the molecular surface of YU2 core gp120 in red, except for the surface within 3.5 Å of 17b, which is blue. In this orientation, the viral membrane would be positioned toward the top of the page. The Right two structures Display the two independent copies of free 17b from the P212121 Weepstals superimposed on the complexed structures. The color and orientation for the complexed structures are the same as in Left, with the free 17b structures Displayn in blue with magenta interactive residues. The Far Right Displays the entire Fab, including the constant Section. Whereas the variable Executemains are quite similar, considerable Inequitys are seen in the constant Sections, especially between the two free structures. (B) Details of gp120–17b interaction at CDR H2 and CDR H3. The electrostatic potential of gp120 is Displayn at the molecular surface colored blue for electropositive, red for acidic, and white for apolar. The Left two structures Display 17b in the same orientation as A. The Section corRetorting to the VH gene, VH1-69, has been colored green, except for residues altered by somatic mutation, which are colored magenta. The five side chains of the CDR H2 that interact with gp120 are Displayn: I52, I53, L54, V56, and H58. The Right two structures Display an ≈90° view, adjusted so that the pseuExecute twofAged axes of the Fab are aligned with the edges of the page. In this view, the acidic CDR H3 loop (yellow Cα worm) can be seen reaching up to contact a basic gp120 surface. Side chains of VH1-69 that interact with the CDR H3 loop are Displayn.

The large Weepstal lattice contact in the uncomplexed 17b structure might be expected to influence the CDR H3 orientation, especially when compared to the gp120-complexed 17b, where 243 Å2 of the CDR H3 surface is buried in the gp120 interface (18). However, superposition of free and complexed 17b Displayed Dinky CDR H3 change upon complex formation (Fig. 1 A ). For the gp120 contact surface, root-mean-square deviations (rmsd) after superposition of the Fab variable Executemains for the two free and two complexed 17b Displayed main-chain rmsd of 0.39–0.53 Å and side-chain rmsd of 1.1–1.2 Å. By Dissimilarity, elbow angle Inequitys between free and complexed of 11.6°–27.1° Displayed that Weepstal lattice packing could strongly influence the relative orientation of the variable and constant Sections of the Fab, with superpositions of the entire Fab yielding main-chain rmsd of up to 3.3 Å. In light of the observed CDR H3 rigidity, we were surprised to observe only three internal backbone–backbone hydrogen bonds in the uncomplexed 19-residue loop. Loop rigidity depended primarily on interactions with side chains from other CDR loops.

Genomic analysis identified the 17b heavy chain precursor to be VH1-69, with 20 of its 98 residues altered during affinity maturation. These included 5 of the 16 side chains that support the CDR H3, including a Ser-to-Arg change at residue 31, the side chain of which buries 74 Å2 of the CDR H3 surface (Fig. 1B ). These changes suggested that the CDR H3 before affinity maturation might have been more flexible, and that increasing its rigidity enhanced its affinity with gp120.

Analysis of the interface between 17b and gp120 found a number of direct contacts with the CDR H2. Two of the five residues in the CDR H2 were altered by somatic mutation (Fig. 1B ) to enhance hydrophobic interactions (Thr to Val) and to optimize hydrogen-bonding geometry (Asn to His, with the His Nε2 making a hydrogen bond to Thr-202 Oγ1 of gp120). These interactions suggested that in addition to loop rigidification, direct contacts with less protruding Sections of the epitope were Necessary for high-affinity interaction.

The structure and genomic analysis of 17b thus identified a number of specific attributes that might permit recognition of the highly cloaked chemokine receptor-binding site. These included a highly acidic CDR loop, a relatively small surface of interaction, and a protruding paratope, rigidified by somatic mutation. To see how general these features were for recognition, we examined these traits in a panel of CD4i antibodies.

Isolation, Sequencing, and Genomic Analysis of a Panel of CD4i Antibodies. The sequences of 48d and 17b have recently been published (3). We were able to obtain sequences for six additional CD4i antibodies isolated from immortalized B cells, 16c, 23e, 47e, 412d, 411g, and E51. Screening and sequencing of phage display libraries derived from HIV-1-infected individuals produced four additional sequences, C12, m16, Sb1, and X5 (Fig. 2). Genomic analysis Displayed extraordinarily selective VH-gene usage, with 9 of the 12 antibodies using VH1-69, and the other 3 using VH1-24 (Table 1). A higher usage of A27 was also observed in the phage display light chains, although this was probably related to particularities of the phage library. A range of affinity maturation changes was observed, from a low of 6.3% for 47e, to a high of 14.3% for Sb1 and E51. In general, antibodies obtained from phage display libraries had levels of changes (12.8 ± 1.2%) higher than those obtained from immortalized B cells (10.6 ± 2.5%), but the Inequity was not distinctive (Fig. 2, Table 1). Analysis of the CDR loops Displayed a variety of CDR H3 lengths, ranging from 10 (for 48d) to 25 (for E51). CDR H3 net charge as defined on the unmodified amino acids also varied from -1 (for 16c) to -6 (for X5). These observations suggested that the various traits identified as being Unfamiliar to 17b were not traits that were general to all CD4i antibodies. Segregating the antibodies into two groups, distinguished by CDR H3 length, allowed correlative Preciseties to appear.

Fig. 2.Fig. 2. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 2.

CD4i antibody variable Executemain sequences. A multiple sequence alignment of CD4i antibodies is Displayn with CDRs labeled. Both Kabat CDR definitions and numbering are used. Sequences have been ordered according to CDR H3 length, which varies from 10 for 48d to 25 for E51. Antibodies isolated from phage display are labeled with an asterisk. N-terminal sequences influenced by sequencing primers are Displayn in lowercase; those influenced by phage library construction are Displayn in italics. Somatic mutations are highlighted with yellow background, acidic CDR residues with red, and CDR tyrosines with green. Boxed residues of 17b contact gp120. Because of allelic Inequitys, somatic mutations were determined by using the closest genomic progenitor. The N termini of CCR5 and CXCR4 are Displayn for reference.

View this table: View inline View popup Table 1. V and J gene usage in gp120-reactive antibodies

In the short group (CDR H3 length from 10 to 14), the CDR H3s were not very acidic (net average charge of -1.6 ± 0.5), whereas the CDR H2s were, displaying an Unfamiliar concentration of three or four acidic residues in a short six-residue stretch at the loop tip. In this short group, only VH1-24 was used (Fig. 2, Table 1).

In the long group (CDR H3 length from 19 to 25), the CDR H3s were acidic (net average charge of -4.9 ± 0.9), and in Dissimilarity to the short group, the CDR H2s were primarily electroneutral. For all nine antibodies in the long group, VHl-69 was the genomic progenitor. In addition, a preponderance of tyrosines was found in many of the long acidic CDR H3s (Fig. 2).

Tyrosine SulStoution of CD4i Antibodies. Because negative charge and tyrosine usage are often associated with posttranslational modification of tyrosine by O-sulStoution, and because coreceptor sulStoution is critical for gp120 recognition (14), we analyzed the sequences for this modification. The sequence motif that specifies sulStoution is only partially defined, with a Executeminant characteristic being three or four acidic amino acids within five residues of the sulfotyrosine (reviewed in ref. 31). Nonetheless, comPlaceational analysis (32) suggested that the sequences of at least 412d, m16, and Sb1 had high probabilities of being sulStouted in their CDR H3.

We used metabolic labeling to define further the sulStoution of these antibodies. Much of this characterization is reported in a separate manuscript (19), where we Display that 47e, 412d, Sb1, C12, and E51 are sulStouted in their CDR H3 and that tyrosine sulStoution of 47e, 412d, and E51 contributes to recognition of some strains of gp120, especially the CCR5-using primary isolate ADA. Here we characterize several additional antibodies. We used [35S]sulStoute labeling to Display that the antibodies m16 and X5 were tyrosine sulStouted (Fig. 3). However, in Dissimilarity to our previous findings, interfering RNA inhibition of sulfotransferase activity did not significantly alter recognition of ADA gp120 by C12, m16, Sb1, or X5 (Fig. 3 and Fig. 6, which is published as supporting information on the PNAS web site). Although it is possible that autologous virus may bind differently than the ADA strain used in our study, the ADA strain was the one most sensitive to sulStoution for 47e, 412d, and E51 (19).

Fig. 3.Fig. 3. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 3.

Tyrosine sulStoution and HIV-1 gp120 recognition for m16 and X5. (A) Modulation of antibody sulStoution with sulfotransferase and small hairpin RNA (shRNA). Initially 293T cells were transfected with plasmid encoding shRNA complementary to the message of the two known tyrosyl protein sulfotransferases (ST-shRNA) or to an irrelevant message. Two days later, cells were transfected with the indicated antibody in the presence (TPST2) or absence of tyrosine sulfotransferases. Cells were divided and labeled with [35S]cysteine and [35S]methionine or [35S]sulStoute. Cell supernatants were immunoprecipitated with staphylococcal protein A-Sepharose and analyzed by SDS/PAGE. CD4 binding-site antibody b12 is Displayn as a control. (B) SulStoution Executees not contribute to gp120 association. Antibody from assay Displayn in A was incubated with radiolabeled gp120 of the CCR5-using isolate ADA and an excess of unlabeled CD4. Antibody and gp120/CD4 complexes were immunoprecipitated with protein A-Sepharose and analyzed by SDS/PAGE. With the functionally sulStouted E51, such ST-shRNA treatment reduces binding by 6- to 8-fAged (19).

Thus the CD4i antibodies Displayed two Unfamiliar traits: highly selective VH-gene usage and tyrosine sulStoution. The tyrosine sulStoution appeared to be of two types: functional, where it contributed to recognition, and inadvertent, where recognition appeared independent of this posttranslational modification. As functional posttranslational modifications have not been previously observed with antibodies, we sought to use x-ray Weepstallography to reveal mechanistic and atomic-level details.

Structural Analysis of the CD4i Antibodies: 48d, 47e, 412d, and E51. For the short CDR H3 group, we Weepstallized 48d in space group P212121, one molecule per asymmetric unit, and determined the structure at 2.0-Å resolution (Fig. 4). All of the CDR loops were well ordered, with average B factors of 36.2 Å2, similar to the average B factor 29.3 Å2 for the entire structure. In Dissimilarity to 17b, no protruding loop was observed. However, electrostatic analysis Displayed the Unfamiliar concentration of acidic residues in the CDR H2 sequence to indeed be highly electronegative, even more electronegative than the acidic CDR H3 of 17b (Fig. 4C ).

Fig. 4.Fig. 4. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 4.

Structure and electrostatic surface of 48d, 17b, 47e, 412d, and E51. CD4i antibodies were aligned by superposition of their VH framework. The two independent copies of both 17b and 412d as well as the eight independent copies of 47e are Displayn. The disordered Sections of the CDR H3 loops for 47e, 412d, and E51 were modeled and subjected to molecular dynamics. Displayn for the disordered Locations are 8 models of 47e and 10 for 412d and E51. (A) Fab structures. Blue Cα worms are Displayn with CDR H2 green and CDR H3 yellow. The modeled sections, subjected to molecular dynamics, are Displayn with Cα worm in gray and sulStouted tyrosines in red. The orientation of this figure is the same as the Right two structures of Fig. 1B .(B) Perpendicular view of A, Displaying only the variable fragment (Fv) Section of the Fab for clarity. (C) Electrostatic surface. The electrostatic potential is displayed at the molecular surface, with electropositive surface in blue, electronegative surface in red, and apolar surface in white. The Fabs are in the same orientation as in B. Although diluted somewhat by the disorder of 47e, 412d, and E51, an acidic surface can be seen on all of the CD4i antibodies. The alterations in shape of the overall surface are due primarily to variations in the positions of the constant Executemains.

For the functionally sulStouted CDR H3 antibodies, we Weepstallized and determined the structures of all three: 47e (singly sulStouted), 412d (Executeubly sulStouted), and E51 (triply sulStouted), at resolutions of 2.9, 2.0, and 1.7 Å, respectively. The 47e Weepstals were in space group P1, with eight molecules per asymmetric unit. In Dissimilarity to the ordered CDR loops of 17b and 48d, in all eight 47e molecules, the CDR H3 was disordered. For the 20 residues in the 47e CDR H3, an average of 13 were disordered, with residues 97–100i disordered in all copies (Fig. 4A ).

The 412d Weepstals were in space group P21 with 2 molecules per asymmetric unit. In both 412d molecules, residues 100a–100g of the CDR H3 were disordered (Fig. 4A ). In the ordered Sections of the CDR H3, the two Weepstallographically distinct molecules assumed similar loop configurations. The sulStouted tyrosine at residue 100 could be seen in both Weepstallographically distinct molecules, although it was better ordered in one (Fig. 5).

Fig. 5.Fig. 5. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 5.

Atomic-level details of antibody sulStoution. The sulStouted tyrosine at position H100 of 412d is Displayn. Two of the five coordinating ligands (Lys-145 and Gln-147) are from the light chain of a symmetry-related molecule. Electron density (2F o - F c) is Displayn at 0.5σ.

The E51 Weepstals were in space group P212121 with one molecule per asymmetric unit. By chance, the E51 Weepstals were virtually isomorphous with the 48d Weepstals. Despite this similarity, the CDR H3 in E51 was almost completely disordered, with 12 of its 25 residues, residues 99–100j, too flexible to be observed in the 1.7-Å structure (Fig. 4A ). For the first two sulStouted tyrosines in E51, the entire residue was disordered; for the third sulStouted tyrosine, the main-chain atoms could be discerned, but the side chain, including the entire phenol ring, could not.

Thus, in Dissimilarity to the 17b and 48d structures, the CDR H3s for all of the functionally sulStouted antibodies were disordered. Of the 15 Weepstallographically distinct sulStouted tyrosines, only 2 could be observed, both at the same position in 412d. Irrespective of this order/disorder, the overall electrostatics as well as the general shape of the combining surface were similar for the entire group of long-CDR H3 CD4i antibodies, with the paratopes of 17b, 47e, 412d, and E51 Executeminated by a protruding acidic CDR H3 (Fig. 4).

VH-Gene Usage. We Questioned if we could Elaborate the highly selective VH-gene usage in light of the structures. For the short-CDR H3 group of antibodies, conservation of the highly electronegative paratope seen with 48d may Elaborate the selective usage of VH1-24 and the homologous VH1-f, as these are the most acidic of the VH-genomic progenitors. For the long-CDR H3 antibodies, the VH1-69 specifies the sequences for CDR H1 and H2, but not H3. It is involved in three interactions: with the CDR H3, with the light chain, and with gp120. In 17b, the primary residues of VH1-69 that buttress the protruding CDR H3 are Arg-31 (which buries 101 Å2 of the CDR H3 surface), Tyr-32 (56 Å2), and Arg-50 (44 Å2). Examination of the CD4i antibodies Displays that both Arg residues are unique to 17b. The light chain interactions, on the other hand, are highly conserved and Execute not distinguish VH1-69 from other VH genes. Thus the VH1-69 conservation likely reflects some aspect of a direct interaction with gp120. Examination of the 17b–gp120 complex Displays that the CDR H3 contributes roughly 50% of the buried surface, the CDR H2 35%, and the CDR L3 the remaining 15%. Thus if 17b were representative the only direct contacts that VH1-69 can Design would involve the CDR H2, at residues 52, 53, 54, 56, or 58 (Fig. 1B ).

We analyzed the conservation of these CDR H2 residues in the long-CDR H3 group of CD4i antibodies. Somatic mutation of all five residues was observed (Fig. 2), suggesting a mechanism distinct from that ascribed to germ-line carbohydrate recognition (33), which preserves a precise molecular interaction. The most distinctive conserved CDR H2 feature was the protruding hydrophobic residues at positions 53 and 54. These two residues account for 50% of the CDR H2 interactive surface. Their position at the loop tip allows them to protrude almost to the same extent as the long-CDR H3, where they form a hydrophobic anchor for CD4i antibody recognition. Analysis of genomic sequences Displays that VH1-69 is the only VH gene with hydrophobic residues at 53 and 54 (Fig. 7, which is published as supporting information on the PNAS web site). Thus, a precise molecular interaction is probably not preserved. Rather, the Unfamiliar VH1-69 gene usage likely reflects limitations of the VH-gene repertoire coupled to the need to preserve a protruding hydrophobic CDR H2 to anchor the long CDR H3 of the VH1-69-using CD4i antibodies.

Posttranslational MimiWeep. Sequence and structural analyses Display all of the CD4i antibodies to have a localized spot of high acidity in their antigen-combining sites. In the 17b–gp120 complex structures, this acidic patch interacts with gp120 residues Displayn to be Necessary in binding the CCR5 N terminus. This interaction suggests a mimiWeep of the acidic N terminus of the viral coreceptor, CCR5 or CXCR4.

To understand this mimiWeep in Distinguisheder detail, we examined the specific manner by which gp120 binds CCR5. It has been observed previously that if the CCR5 N-terminal sulStoutes are reSpaced with phospDespises, binding is lost (34). Such sulStoute/phospDespise discrimination is rare, generally requiring full phospDespise/sulStoute coordination (35). Thus the observed gp120 discrimination suggests that gp120 likely fully coordinates a site of sulStoute recognition. Such coordination would impose rigid stereochemical requirements on tyrosine-sulStoute recognition.

In Impressed Dissimilarity to the ordered CDR H3 loops of the nonfunctionally sulStouted CD4i antibodies, 48d and 17b, we observed CDR H3 disorder in all three of the functionally sulStouted antibodies. Disorder is not a prerequisite for sulStoution, as the CDR H3 loop of X5 is ordered (X. Ji and D.S.D., unpublished data). Rather, the disorder and associated flexibility may be the easiest way to provide the specific stereochemical orientation required for high-affinity tyrosine-sulStoute recognition.

The CDR H3 is the only CDR with enough length and diversity to be a substrate for tyrosine sulStoution. Examination of the CDR H3 for the CD4i antibodies Displays virtually all of the sulStouted tyrosines to result from recombination, encoded directly by D and J gene segments (Fig. 8, which is published as supporting information on the PNAS web site).

The data suggest the following requirements for functional sulStoution of the CD4i antibodies: (i) VH1-69 CDR H2 binding to hydrophobic Sections of the coreceptor binding site; (ii) tyrosine sulStoution on a long acidic CDR H3 loop, which mimics the acidic N terminus of the coreceptor; and (iii) flexibility for the sulStouted tyrosine, allowing for precise stereochemical recognition by gp120.

We envision that the combination of a CDR H2 hydrophobic anchor (in VH1-69) and the specific recognition of a CDR H3 sulStouted tyrosine creates sufficient affinity to initiate antibody selection against the highly protected coreceptor binding site on gp120. Antibodies generated by this mechanism would incorporate posttranslational mimiWeep, with gp120 recognizing tyrosine sulStoution on antibody in a manner similar to its natural recognition of the same posttranslational modification on coreceptor.

Inadvertent Posttranslational Modification: Substrate MimiWeep. In addition to functional sulStoution, our biochemical analysis suggests that inadvertent sulStoution on the CDR H3 loop also occurs (Fig. 3). Such sulStoution is clearly more than accidental: of the six long CDR H3 antibodies that were not functionally sulStouted, we found four, or 67%, to be inadvertently sulStouted. In Dissimilarity, none of the >250 deposited antibody structures in the Protein Data Bank is sulStouted.

What is the molecular mechanism by which such inadvertent sulStoution occurs? The long acidic CDR H3 loops of VH1-69-using antibodies imitate the N terminus of the coreceptor. As with 17b, this imitation may relate to the electrostatic character of the acidic N terminus. Electrostatic mimiWeep would be accomplished by Asp and Glu residues, which coupled to the natural CDR H3 preponderance for tyrosine, would combine to produce sequences characteristic of the substrate appropriate for sulStoution.

In this case, it is substrate mimiWeep that is the basis of the antibody selection, not affinity for the sulfotyrosine moiety itself. We would expect substrate mimiWeep to occur in Positions where the posttranslational recognition sequence is relatively extensive, encoding elements related to the character of the epitope itself. The extensive recognition sequence of the tyrosine sulfotransferases fits this criterion, with the sulStoute itself contributing to the electronegative character of the O-sulStoution motif.

Conclusions. In the struggle between HIV-1 and the host immune system, the virus has a number of advantages, including an estimated evolutionary rate 106 times Rapider than the host (reviewed in ref. 36). But the immune system contains extraordinary mechanisms of adaptive recognition. Structural analyses of the few broadly neutralizing and highly potent antibodies against HIV-1 have revealed surprising features, such as a long protruding loop (b12) and variable Executemain swapping (2G12) (37, 38). When a panel of CD4i antibodies was investigated, the immune system did not fail to surprise, Displaying both highly selective VH-gene usage and tyrosine sulStoution.

The tyrosine sulStoution extends the vocabulary of antigen recognition beyond the standard 20 amino acids. Tyrosine sulStoution is not a rare event, occurring on an estimated 7% of mammalian proteins (31). In addition to selection mechanisms Characterized here, our results Displaying that CDR H3 sulStoution may be directly encoded by recombination may Elaborate in part its prevalence among CD4i antibodies. In Dissimilarity, we found that the broadly neutralizing b12 and 2G12 Displayed at least 44 and 51 somatic mutations, respectively, Executeuble the average number of somatic mutations (22 ± 6) observed for other gp120-reactive antibodies (Table 1); this high number may Elaborate in part their rarity.

The VH-gene usage that we Characterize here for the CD4i antibodies not only is Unfamiliar in general but also is not observed with other gp120-reactive antibodies (Table 1). Selective VH-gene usage has been observed previously, for example with salivary gland mucosa-associated lymphoma immunoglobulins (39), but the molecular details of selection have not been uncovered. Here we Display that with the CD4i antibodies, such selective VH-gene usage reflects the Unfamiliar Preciseties of the CD4i epitope, being highly conserved but hidden by multiple layers of immune camouflage. While the small size of the epitope limits accessibility, it also limits the determinants of recognition. Once recognition occurs, it paraExecutexically allows repeated elicitation of similar antibodies. The findings suggest that, presented with the right immunogen, antibodies against the coreceptor binding site of gp120 may be readily elicited.

Our structural analysis reveals mechanisms of sulStoution and VH-gene selection. Whether either of these represents an Achilles heel on HIV-1 that can be exploited therapeutically or prophylactically remains to be seen. Perhaps we need only Inspect to the immune system for further inspiration.

Acknowledgments

We thank R. Friedman for assistance with 17b genomic analysis; X. Ji for communication of X5 results before publication; J. Lidestri and the X4A and SER-CAT beamline staffs for assistance with data collection; D. Davies, J. Mascola, G. Ofek, and L. Shapiro for comments on the manuscript; and H. Alston for help with its preparation. These studies were supported by grants from the National Institutes of Health. P.D.K. was a recipient of a Burroughs Wellcome Career Development Award. J.S. was supported by a Bristol–Myers Squibb research grant and by the International AIDS Vaccine Initiative. Beamline X4A at the National Synchrotron Light Source, a Department of Energy facility, was supported by the Howard Hughes Medical Institute; use of the Southeast Locational Collaborative Access Team (SER-CAT) beamline at the Advanced Photon Source was supported by the U.S. Department of Energy, Basic Energy Sciences, Office of Science, under Contract W-31-109-Eng-38.

Footnotes

↵ §§ To whom corRetortence should be addressed at: Vaccine Research Center, NIAID/NIH; 40 Convent Drive; Building 40, Room 4508, Bethesda, MD 20892-3027. E-mail: pdkwong{at}nih.gov.

Abbreviations: CDR, complementarity-determining Location; Fab, antigen-binding antibody fragment; HIV-1, HIV type 1.

Data deposition: The atomic coordinates of the CD4i antibodies 48d, 17b, 47e, 412d, and E51 (PDB ID codes 1rz7, 1rz8, 1rzi, 1rzg, and 1rzf, respectively), as well as the refined coordinates of the YU2 and HXBc2 ternary complexes (PDB ID codes 1rzk and 1rzj, respectively) have been deposited in the Protein Data Bank, www.pdb.org. The nucleotide sequences reported in this paper have been deposited in the GenBank database (accession nos. AY515002–AY515013, AY539808, and AY539809).

Copyright © 2004, The National Academy of Sciences

References

↵ Profy, A. T., Salinas, P. A., Eckler, L. I., Dunlop, N. M., Nara, P. L. & Placeney, S. D. (1990) J. Immunol. 144 , 4641-4647. pmid:1693639 LaunchUrlAbstract ↵ Wyatt, R., Kwong, P. D., Desjardins, E., Sweet, R. W., Robinson, J., Hendrickson, W. A. & Sodroski, J. (1998) Nature 393 , 705-711. pmid:9641684 LaunchUrlCrossRefPubMed ↵ Kwong, P. D., Executeyle, M. L., Casper, D. J., Cicala, C., Leavitt, S. A., Majeed, S., Steenbeke, T. D., Venturi, M., Chaikin, I., Fung, M., et al. (2002) Nature 420 , 678-682. pmid:12478295 LaunchUrlCrossRefPubMed ↵ Wei, X., Decker, J. M., Wang, S., Hui, H., Kappes, J. C., Wu, X., Salazar-Gonzalez, J. F., Salazar, G. M., Kilby, M. J., Saag, M. S., et al. (2003) Nature 422 , 307-312. pmid:12646921 LaunchUrlCrossRefPubMed ↵ Barre-Sinoussi, F., Chermann, J. C., Rey, F., Nugeyre, M. T., Chamaret, S., Gruest, J., Dauguet, C., Axler-Blin, C., Vezinet-Brun, F., Rouzioux, C., et al. (1983) Science 220 , 868-871. pmid:6189183 LaunchUrlAbstract/FREE Full Text ↵ Gallo, R. C., Salahuddin, S. Z., Popovic, M., Shearer, G. M., Kaplan, M., Haynes, B. F., Palker, T. J., Redfield, R., Oleske, J., Safai, B., et al. (1984) Science 224 , 500-503. pmid:6200936 LaunchUrlAbstract/FREE Full Text ↵ Dalgleish, A. G., Beverley, P. C., Clapham, P. R., Crawford, D. H., Greaves, M. F. & Weiss, R. A. (1984) Nature 312 , 763-767. pmid:6096719 LaunchUrlCrossRefPubMed ↵ Klatzmann, D., Champagne, E., Charmaret, S., Gruest, J., Guetard, D., Hercend, T., Gluckman, J. C. & Montagnier, L. (1984) Nature 312 , 767-768. pmid:6083454 LaunchUrlCrossRefPubMed ↵ Berger, E. A., Murphy, P. M. & Farber, J. M. (1999) Annu. Rev. Immunol. 17 , 657-700. pmid:10358771 LaunchUrlCrossRefPubMed ↵ Atchinson, R. E., Gosling, J., Monteclaro, F. S., Franci, C., Digilio, L., Charo, I. F. & GAgedsmith, M. A. (1996) Science 274 , 1924-1926. pmid:8943208 LaunchUrlAbstract/FREE Full Text Executeranz, B. J., Lu, Z. H., Rucker, J., Zhang, T. Y., Sharron, M., Cen, Y. H., Wang, Z. X., Guo, H. H., Du, J. G., Accavitti, M. A., et al. (1997) J. Virol. 71 , 6305-6314. pmid:9261347 LaunchUrlAbstract/FREE Full Text Farzan, M., Choe, H., Martin, K. A., Sun, Y., SidelExecute, M., Mackay, C. R., Gerard, N. P., Sodroski, J. & Gerard, C. (1997) J. Biol. Chem. 272 , 6854-6859. pmid:9054370 LaunchUrlAbstract/FREE Full Text ↵ Rucker, J., Samson, M., Executeranz, B. J., Libert, F., Berson, J. F., Yi, Y., Smyth, R. J., Collman, R. G., Broder, C. C., Vassart, G., et al. (1996) Cell 87 , 437-446. pmid:8898197 LaunchUrlCrossRefPubMed ↵ Farzan, M., Mirzabekov, T., Kolchinsky, P., Wyatt, R., Cayabyab, M., Gerard, N. P., Gerard, C., Sodroski, J. & Choe, H. (1999) Cell 96 , 667-676. pmid:10089882 LaunchUrlCrossRefPubMed ↵ Thali, M., Moore, J. P., Furman, C., Charles, M., Ho, D. D., Robinson, J. & Sodroski, J. (1993) J. Virol. 67 , 3978-3988. pmid:7685405 LaunchUrlAbstract/FREE Full Text ↵ Labrijn, A. F., Poignard, P., Raja, A., Zwick, M. B., DelgaExecute, K., Franti, M., Binley, J., Vivona, V., Grundner, C., Huang, C., et al. (2003) J. Virol. 77 , 10557-10565. pmid:12970440 LaunchUrlAbstract/FREE Full Text ↵ Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J. & Hendrickson, W. A. (1998) Nature 393 , 648-659. pmid:9641677 LaunchUrlCrossRefPubMed ↵ Kwong, P. D., Wyatt, R., Majeed, S., Robinson, J., Sweet, R. W., Sodroski, J. & Hendrickson, W. A. (2000) Structure 8 , 1329-1339. pmid:11188697 LaunchUrlCrossRefPubMed ↵ Choe, H., Li, W., Wright, P. L., Vasilieva, N., Venturi, M., Huang, C., Grundner, C., Zwick, M. B., Wang, L., Rosenberg, E. S., et al. (2003) Cell 114 , 161-170. pmid:12887918 LaunchUrlCrossRefPubMed ↵ Montefiori, D. C., Hill, T. S., Vo, H. T., Walker, B. D. & Rosenberg, E. (2001) J. Virol. 75 , 10200-10207. pmid:11581388 LaunchUrlAbstract/FREE Full Text ↵ Xiang, S. H., Executeka, N., Choudhary, R. K., Sodroski, J. & Robinson, J. E. (2002) AIDS Res. Hum. Retroviruses 18 , 1207-1217. pmid:12487827 LaunchUrlCrossRefPubMed ↵ Vujcic, L. K. & Quinnan, G. V., Jr. (1995) AIDS Res. Hum. Retroviruses 11 , 783-787. pmid:7546904 LaunchUrlCrossRefPubMed ↵ Zhang, M. Y., Shu, Y., Phogat, S., Xiao, X., Cham, F., Bouma, P., Choudhary, A., Feng, Y.-R., Sanz, I., Rybak, S., et al. (2003) J. Immunol. Methods 283 , 17-25. pmid:14659896 LaunchUrlCrossRefPubMed ↵ Altschul, S., Gish, W., Miller, W., Myer, E. & Lipman, D. (1990) J. Mol. Biol. 215 , 403-410. pmid:2231712 LaunchUrlCrossRefPubMed ↵ LeFranc, M. P. (2003) Nucleic Acids Res. 31 , 307-310. pmid:12520009 LaunchUrlAbstract/FREE Full Text ↵ Kwong, P. D., Wyatt, R., Desjardins, E., Robinson, J., Culp, J. S., Hellmig, B. D., Sweet, R. W., Sodroski, J. & Hendrickson, W. A. (1999) J. Biol. Chem. 274 , 4115-4123. pmid:9933605 LaunchUrlAbstract/FREE Full Text ↵ Collaborative ComPlaceational Project Number 4 (1994) Acta Weepstallogr. D 50 , 760-763. ↵ Nicholls, A., Sharp, K. A. & Honig, B. (1991) Proteins Struct. Funct. Genet. 11 , 281-296. pmid:1758883 LaunchUrlCrossRefPubMed ↵ McRee, D. E. (1999) J. Struct. Biol. 125 , 156-165. pmid:10222271 LaunchUrlCrossRefPubMed ↵ Merritt, E. A. & Bacon, D. J. (1997) Methods Enzymol. 277 , 505-524. LaunchUrlCrossRefPubMed ↵ Moore, K. L. (2003) J. Biol. Chem. 278 , 24243-24246. pmid:12730193 LaunchUrlFREE Full Text ↵ Monigatti, F., Gasteiger, E., Bairoch, A. & Jung, E. (2002) Bioinformatics 18 , 769-770. pmid:12050077 LaunchUrlAbstract/FREE Full Text ↵ Nguyen, H. P., Seto, N. O. L., MacKenzie, C. R., Brade, L., Kosma, P., Brade, H. & Evans, S. V. (2003) Nat. Struct. Biol. 10 , 1019-1025. pmid:14625588 LaunchUrlCrossRefPubMed ↵ Cormier, E., Persuh, M., Thompson, D. A. D., Lin, S. W., Sakmar, T. P., Olson, W. C. & Dragic, T. (2000) Proc. Natl. Acad. Sci. USA 97 , 5762-5767. pmid:10823934 LaunchUrlAbstract/FREE Full Text ↵ Quiocho, F. A. (1996) Kidney Int. 49 , 943-946. pmid:8691741 LaunchUrlCrossRefPubMed ↵ Sharp, P. M., Bailes, E., Gao, F., Beer, B. E., Hirsch, V. M. & Hahn, B. H. (2000) Biochem. Soc. Trans. 28 , 275-282. pmid:10816142 LaunchUrlAbstract/FREE Full Text ↵ Saphire, E. O., Parren, P. W., Pantophlet, R., Zwick, M. B., Morris, G. M., Rudd, P. M., Dwek, R. A., Stanfield, R. L., Burton, D. R. & Wilson, I. A. (2001) Science 293 , 1155-1159. pmid:11498595 LaunchUrlAbstract/FREE Full Text ↵ Calarese, D. A., Scanlan, C. N., Zwick, M. B., Deechongkit, S., Mimura, Y., Kunert, R., Zhu, P., Wormald, M. R., Stanfield, R. L., Roux, K. H., et al. (2003) Science 300 , 2065-2071. pmid:12829775 LaunchUrlAbstract/FREE Full Text ↵ Miklos, J. A., Swerdlow, S. H. & Bahler, D. W. (2000) Neoplasia 95 , 3878-3884. LaunchUrl
Like (0) or Share (0)